Anavex Life Sciences (Anavex Life Sciences) Cash-to-Debt

: No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Anavex Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Anavex Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Anavex Life Sciences's Cash-to-Debt or its related term are showing as below:

AVXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.23 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Anavex Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 1.23. And the median was No Debt.

AVXL's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs AVXL: No Debt

Anavex Life Sciences Cash-to-Debt Historical Data

The historical data trend for Anavex Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

No Debt

Anavex Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison

For the Biotechnology subindustry, Anavex Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Cash-to-Debt falls into.

Anavex Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Anavex Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Anavex Life Sciences had no debt ⁽¹⁾.

Anavex Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Anavex Life Sciences had no debt ⁽¹⁾.

Anavex Life Sciences (NAS:AVXL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Anavex Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (Anavex Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

12X1:Germany 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Executives

Christopher U Missling	director, officer: President, CEO, CFO, Treasurer, other: Secretary	61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos	10 percent owner	14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma	director	445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o.	director	REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch	officer: PFO & Treasurer	51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden	director	PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas	director	FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh	director, officer: Executive Director
John Robert Chisholm	director	16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry	director	1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley	director	14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach	director, officer: President CEO CFO	4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers	director	27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052